Using low-dose ketamine to relieve pain during burn wound care
A Randomized, Placebo-Controlled, Double-Blind Evaluation of Low-Dose Ketamine Infusion During Burn Wound Care Procedures to Improve Pain Intensity and Reduce Opioid Consumption
This study is testing if low-dose ketamine can help relieve pain better than standard opioid treatments during wound care for people with burn injuries.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Tennessee Academic / other |
| Locations | 1 site (Memphis, Tennessee) |
| Trial ID | NCT06506565 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of low-dose ketamine infusions during wound care for patients with burn injuries. The aim is to assess whether ketamine can provide better pain relief compared to the current standard of care, which primarily relies on opioids like fentanyl and midazolam. By potentially reducing opioid use and minimizing adverse effects, this approach seeks to improve patient comfort during painful procedures. Participants will receive ketamine alongside saline during their treatment.
Who should consider this trial
Good fit: Ideal candidates are adults admitted to the burn service with thermal injuries who can consent and report their pain levels.
Not a fit: Patients who are under 18, pregnant, incarcerated, or have contraindications to ketamine will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved pain management for burn patients while reducing reliance on opioids.
How similar studies have performed: Other studies have shown promising results with ketamine for pain management, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Admitted to burn service with thermal injury Exclusion Criteria: * unable/unwilling to consent within 72 hours * unable to report NRS * known contraindication to ketamine * \< than 18 years of age * pregnant * incarcerated * TBSA over 50 %
Where this trial is running
Memphis, Tennessee
- Regional One Health — Memphis, Tennessee, United States (Recruiting)
Study contacts
- Study coordinator: David M Hill, Pharm.D.
- Email: dhill19@uthsc.edu
- Phone: 1-901-545-7100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.